Neurotransmitter abnormalities and response to supplementation in SPG11

Adeline Vanderver; Davide Tonduti; Sarah Auerbach; Johanna L. Schmidt; Sumit Parikh; Gordon C. Gowans; Kelly E. Jackson; Pamela L. Brock; Marc Patterson; Michelle Nehrebecky; Rena Godfrey; Wadih M. Zein; William Gahl; Camilo Toro

doi:10.1016/j.ymgme.2012.05.020

Neurotransmitter abnormalities and response to supplementation in SPG11

Adeline Vanderver
, Davide Tonduti
, Sarah Auerbach
, Johanna L. Schmidt
, Sumit Parikh
, Gordon C. Gowans
, Kelly E. Jackson
, Pamela L. Brock
, Marc Patterson
, Michelle Nehrebecky
, Rena Godfrey
, Wadih M. Zein
, William Gahl
, Camilo Toro

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Objective: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11 patients and describe treatment with l-dopa/carbidopa and sapropterin. Design: Case reports. Setting: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. Patients: Four SPG11 patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. Interventions: l-Dopa/carbidopa and sapropterin. Results: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to l-dopa as well as sapropterin. Conclusions: In the SPG11 patient with extrapyramidal symptoms, a trial of l-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.

Original language	English
Pages (from-to)	229-233
Number of pages	5
Journal	Molecular Genetics and Metabolism
Volume	107
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ymgme.2012.05.020
State	Published - Sep 2012

Keywords

Dopa responsive dystonia
Neurotransmitter disorder
SPG11
Spastic paraparesis

Access to Document

10.1016/j.ymgme.2012.05.020

Cite this

Vanderver, A., Tonduti, D., Auerbach, S., Schmidt, J. L., Parikh, S., Gowans, G. C., Jackson, K. E., Brock, P. L., Patterson, M., Nehrebecky, M., Godfrey, R., Zein, W. M., Gahl, W., & Toro, C. (2012). Neurotransmitter abnormalities and response to supplementation in SPG11. Molecular Genetics and Metabolism, 107(1-2), 229-233. https://doi.org/10.1016/j.ymgme.2012.05.020

@article{65a4f37eed26497dbf69b997ac86fe21,

title = "Neurotransmitter abnormalities and response to supplementation in SPG11",

abstract = "Objective: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11 patients and describe treatment with l-dopa/carbidopa and sapropterin. Design: Case reports. Setting: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. Patients: Four SPG11 patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. Interventions: l-Dopa/carbidopa and sapropterin. Results: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to l-dopa as well as sapropterin. Conclusions: In the SPG11 patient with extrapyramidal symptoms, a trial of l-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.",

keywords = "Dopa responsive dystonia, Neurotransmitter disorder, SPG11, Spastic paraparesis",

author = "Adeline Vanderver and Davide Tonduti and Sarah Auerbach and Schmidt, \{Johanna L.\} and Sumit Parikh and Gowans, \{Gordon C.\} and Jackson, \{Kelly E.\} and Brock, \{Pamela L.\} and Marc Patterson and Michelle Nehrebecky and Rena Godfrey and Zein, \{Wadih M.\} and William Gahl and Camilo Toro",

note = "Funding Information: Patients 1, 2 and 3 were enrolled via the Myelin Disorders Bioregistry Program and all patients were evaluated as part of the Undiagnosed Disease Program at the National Institutes of Health (NIH). Thanks are given to the administrative staff of the Undiagnosed Disease Program (UDP) for their logistical efforts. Thanks are also given to referring physicians and patients described in this report, in particular Dr. Steven Vernino for his assistance on outpatient care in one case. Interpretation of neurotransmitter abnormalities was assisted by Dr. Philip Pearl at Children's National Medical Center. The contributions of A.V. were supported by the intramural program at the National Human Genome Research Institute, NIH . Assistance in description of mutation status was provided by Khalida Liaquat, MS, CGC, Genetic Counselor at Athena Diagnostics.",

year = "2012",

month = sep,

doi = "10.1016/j.ymgme.2012.05.020",

language = "English",

volume = "107",

pages = "229--233",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

number = "1-2",

}

TY - JOUR

T1 - Neurotransmitter abnormalities and response to supplementation in SPG11

AU - Vanderver, Adeline

AU - Tonduti, Davide

AU - Auerbach, Sarah

AU - Schmidt, Johanna L.

AU - Parikh, Sumit

AU - Gowans, Gordon C.

AU - Jackson, Kelly E.

AU - Brock, Pamela L.

AU - Patterson, Marc

AU - Nehrebecky, Michelle

AU - Godfrey, Rena

AU - Zein, Wadih M.

AU - Gahl, William

AU - Toro, Camilo

N1 - Funding Information: Patients 1, 2 and 3 were enrolled via the Myelin Disorders Bioregistry Program and all patients were evaluated as part of the Undiagnosed Disease Program at the National Institutes of Health (NIH). Thanks are given to the administrative staff of the Undiagnosed Disease Program (UDP) for their logistical efforts. Thanks are also given to referring physicians and patients described in this report, in particular Dr. Steven Vernino for his assistance on outpatient care in one case. Interpretation of neurotransmitter abnormalities was assisted by Dr. Philip Pearl at Children's National Medical Center. The contributions of A.V. were supported by the intramural program at the National Human Genome Research Institute, NIH . Assistance in description of mutation status was provided by Khalida Liaquat, MS, CGC, Genetic Counselor at Athena Diagnostics.

PY - 2012/9

Y1 - 2012/9

N2 - Objective: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11 patients and describe treatment with l-dopa/carbidopa and sapropterin. Design: Case reports. Setting: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. Patients: Four SPG11 patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. Interventions: l-Dopa/carbidopa and sapropterin. Results: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to l-dopa as well as sapropterin. Conclusions: In the SPG11 patient with extrapyramidal symptoms, a trial of l-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.

AB - Objective: To report the detection of secondary neurotransmitter abnormalities in a group of SPG11 patients and describe treatment with l-dopa/carbidopa and sapropterin. Design: Case reports. Setting: National Institutes of Health in the Undiagnosed Disease Program; Children's National Medical Center in the Myelin Disorders Bioregistry Program. Patients: Four SPG11 patients with a clinical picture of progressive spastic paraparesis complicated by extrapyramidal symptoms and maculopathy. Interventions: l-Dopa/carbidopa and sapropterin. Results: 3/4 patients presented secondary neurotransmitter abnormalities; 4/4 partially responded to l-dopa as well as sapropterin. Conclusions: In the SPG11 patient with extrapyramidal symptoms, a trial of l-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.

KW - Dopa responsive dystonia

KW - Neurotransmitter disorder

KW - SPG11

KW - Spastic paraparesis

UR - https://www.scopus.com/pages/publications/84866167220

U2 - 10.1016/j.ymgme.2012.05.020

DO - 10.1016/j.ymgme.2012.05.020

M3 - Article

C2 - 22749184

AN - SCOPUS:84866167220

SN - 1096-7192

VL - 107

SP - 229

EP - 233

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 1-2

ER -

Neurotransmitter abnormalities and response to supplementation in SPG11

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this